Drugs / AGAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04377932 | Aug 2021 → Aug 2024 overdue | Wilms tumor, liposarcoma, liver cancer, rhabdoid tumor +2 | Baylor College of Medicine | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04377932 ↗ |
| Known as | GPC3-CAR T cells | “GPC3-CAR T cells” NCT04377932 ↗ |
| Modality | Cell therapy | “This research study uses special immune system cells called AGAR T cells, a new experimental treatment.” NCT04377932 ↗ |
| Route | Other | “the cells will be thawed and injected into the patient over 5 to 10 minutes” NCT04377932 ↗ |